Q2 FYE3/2026 Fact Sheet

1. Consolidated Profit and Loss Statement

   FY3/2018 FY3/2019 FY3/2020 FY3/2021 FY3/2022 FY3/2023 FY3/2024 FY3/2025

   FY3/2026

   Amounts less than the indicated unit are rounded down.

   FY3/2026

   Net Sales M

   (Net Sales YoY) %

   Cost of Goods Sold M Gross Profit M

   Gross Profit Margin %

   SG&A Expenses M Operating Profit M

   (Operating Profit YoY) %

   Operating Profit Margin % Non-Operating Income M

   Non-Operating Expenses M Ordinary Profit M

   Ordinary Profit Margin %

   FY A

   42,298

   ＋13.8

   15,722

   26,576

   62.8

   15,904

   10,671

   ＋13.8

   25.2

   259

   200

   10,730

   25.4

   FY A

   45,525

   ＋7.6

   17,703

   27,822

   61.1

   17,295

   10,526

   (1.4)

   23.1

   571

   289

   10,808

   23.7

   FY A

   51,761

   ＋13.7

   22,570

   29,191

   56.4

   18,756

   10,434

   (0.9)

   20.2

   891

   900

   10,425

   20.1

   FY A

   51,286

   (0.9)

   22,622

   28,664

   55.9

   18,296

   10,367

   (0.6)

   20.2

   1,031

   879

   10,519

   20.5

   FY A

   51,469

   ＋0.4

   22,634

   28,835

   56.0

   18,861

   9,973

   (3.8)

   19.4

   316

   285

   10,005

   19.4

   FY A

   51,750

   ＋0.5

   21,855

   29,895

   57.8

   19,057

   10,837

   ＋8.7

   20.9

   293

   224

   10,905

   21.1

   FY A

   51,384

   (0.7)

   20,397

   30,986

   60.3

   20,094

   10,892

   ＋0.5

   21.2

   390

   701

   10,581

   20.6

   FY A

   56,610

   ＋10.2

   22,419

   34,191

   60.4

   21,864

   12,326

   ＋13.2

   21.8

   336

   327

   12,335

   21.8

   Q1 A

   14,616

   ＋4.3

   5,846

   8,769

   60.0

   5,497

   3,272

   ＋2.4

   22.4

   28

   77

   3,223

   22.1

   Q2 A

   14,668

   ＋5.0

   5,880

   8,787

   59.9

   5,439

   3,347

   ＋9.2

   22.8

   66

   13

   3,400

   23.2

   YoY %

   ＋693 ＋5.0

   ＋286 ＋5.1

   ＋407 ＋4.9

   ＋125 ＋2.4

   ＋281 ＋9.2

   ＋109 (258.5)

   (57) (80.7)

   ＋448 ＋15.2

   H1 A

   29,285

   ＋4.6

   11,727

   17,557

   60.0

   10,937

   6,620

   ＋5.7

   22.6

   95

   90

   6,624

   22.6

   YoY %

   ＋1,299 ＋4.6

   ＋705 ＋6.4

   ＋593 ＋3.5

   ＋234 ＋2.2

   ＋359 ＋5.7

   ＋6 ＋7.1

   (90) (49.9)

   ＋456 ＋7.4

   H1

   E*1 29,300

   ＋4.7

   11,900

   17,400

   59.4

   11,100

   6,300

   ＋0.6

   21.5

   100

   100

   6,300

   21.5

   H2 E

   30,000

   ＋4.8

   12,000

   18,000

   60.0

   11,400

   6,600

   ＋8.8

   22.0

   200

   100

   6,700

   22.3

   FY E

   59,300

   ＋4.8

   23,900

   35,400

   59.7

   22,500

   12,900

   ＋4.7

   21.8

   300

   200

   13,000

   21.9

   YoY %

   ＋2,689 ＋4.8

   ＋1,480 ＋6.6

   ＋1,208 ＋3.5

   ＋635 ＋2.9

   ＋573 ＋4.7

   (36) (10.8)

   (127) (39.0)

   ＋664 ＋5.4

   Extraordinary Profit M

   Extraordinary Loss M

   Net Profit Before Tax M Tax Expenses M

   Net Profit M

   Net Profit Margin %

   1

   116

   10,615

   3,137

   7,478

   17.7

   5

   12

   10,801

   3,077

   7,723

   17.0

   3

   4

   10,425

   2,676

   7,748

   15.0

   3

   5,982

   4,540

   2,540

   2,000

   3.9

   44

   8

   10,041

   2,556

   7,484

   14.5

   100

   1,217

   9,789

   2,897

   6,891

   13.3

   13

   19

   10,575

   3,060

   7,515

   14.6

   52

   362

   12,024

   2,707

   9,317

   16.5

   ー

   26

   3,197

   894

   2,302

   15.8

   0

   15

   3,385

   913

   2,472

   16.9

   (7)

   ＋11

   ＋430

   ＋52

   ＋377

   (100.0)

   ＋273.5

   ＋14.6

   ＋6.2

   ＋18.0

   0

   42

   6,582

   1,807

   4,774

   16.3

   (27)

   ＋26

   ＋402

   ＋63

   ＋339

   (100.0)

   ＋163.7

   ＋6.5

   ＋3.6

   ＋7.7

   ー

   50

   6,250

   1,750

   4,500

   15.4

   ー

   50

   6,650

   1,800

   4,850

   16.2

   ー

   100

   12,900

   3,550

   9,350

   15.8

   (52)

   (262)

   ＋875

   ＋842

   ＋32

   (100.0)

   (72.4)

   ＋7.3

   ＋31.1

   ＋0.3

   EPS

   98.51

   96.05

   96.55

   24.91

   93.13

   88.22

   98.73

   131.43

   32.85

   35.24

   68.08

   64.17

   69.13

   133.30

   Proprietary Sales Mix	%	55.4	54.9	50.7	49.9	52.4	54.9	58.8	57.4	55.6	54.7		55.1		56.9	59.4	58.1
   Internatinal Sales Mix	%	ー	ー	ー	ー	ー	ー	1.4	1.9	2.4	2.7		2.6		2.2	2.0	2.1

   R&D Expenses (A)	M	1,121	1,431	1,743	1,667	2,159	2,316	2,366	2,851	662	657	＋68	＋11.7	1,319	＋192	＋17.1	1,607	1,591	3,198	＋347	＋12.2
   Clinical Trials & Regulatory Expenses (B)	M	126	100	80	69	306	19	70	123	33	28	(4)	(14.0)	61	0	(1.5)	91	82	174	＋51	＋41.8
   R&D Investments (A)+(B)	M	1,247	1,532	1,823	1,737	2,465	2,335	2,436	2,974	695	685	＋64	＋10.3	1,381	＋191	＋16.1	1,698	1,674	3,373	＋398	＋13.4
   Capital Expenditure	M	3,630	1,248	2,536	1,382	1,633	976	3,568	1,626	230	225	(139)	(38.3)	455	(226)	(33.2)	1,040	1,450	2,490	＋864	＋53.1
   Depreciation Expenses	M	953	1,176	1,264	1,525	1,611	1,566	1,471	1,779	404	410	(26)	(6.1)	814	(46)	(5.4)	815	847	1,663	(116)	(6.5)
   *1 Disclosed on May 7, 2025

2. Consolidated Balance Sheet

   Amounts less than the indicated unit are rounded down.

   		FY3/2018	FY3/2019	FY3/2020	FY3/2021	FY3/2022	FY3/2023	FY3/2024	FY3/2025	FY3/2026
   		FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2
   											A	vs. Prev.yr-end	%
   Current Assets	M	40,821	41,665	44,077	44,522	45,153	47,130	42,871	44,336	41,322	44,824	＋488	＋1.1
   Tangible Fixed Assets	M	9,914	9,920	11,341	13,111	12,911	12,452	13,434	13,285	13,256	13,145	(140)	(1.1)
   Intangible Fixed Assets	M	576	558	493	505	1,470	2,414	2,292	1,910	1,808	1,724	(186)	(9.8)
   Investments and Others	M	9,668	15,638	19,089	14,822	13,662	12,643	14,910	15,590	14,782	15,581	(9)	(0.1)
   Fixed Assets	M	20,159	26,117	30,923	28,439	28,044	27,510	30,638	30,786	29,847	30,450	(336)	(1.1)
   Total Assets	M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	＋151	＋0.2
   Current Liabilities	M	15,452	14,580	16,093	16,467	14,211	14,381	14,175	14,334	12,034	13,577	(756)	(5.3)
   Long-term Liabilities	M	4,438	6,709	7,500	5,190	4,418	4,063	1,231	874	789	719	(154)	(17.7)
   Total Liabilities	M	19,890	21,289	23,594	21,657	18,629	18,445	15,406	15,208	12,823	14,297	(911)	(6.0)
   Shareholder's Equity	M	41,088	46,496	51,618	51,267	54,362	56,265	57,516	58,675	57,289	59,833	＋1,158	＋2.0
   Accumulated other comprehensiv	M	(11)	(16)	(211)	37	205	(69)	585	1,239	1,056	1,131	(107)	(8.7)
   Share Warrant	M	13	13	ー	ー	ー	ー	ー	ー	ー	12	＋12	ー
   Net Assets	M	41,090	46,493	51,406	51,304	54,567	56,195	58,102	59,914	58,346	60,977	＋1,063	＋1.8
   Total Liabilities and Net Assets	M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	＋151	＋0.2

   Cash and Deposits	M	6,732	8,018	9,555	13,708	16,058	18,357	12,669	11,014	7,467	9,630	(1,384)	(12.6)
   Accounts Receivables	M	12,331	12,178	13,762	13,145	12,437	13,223	13,283	13,830	14,170	14,435	＋604	＋4.4
   Inventory	M	13,579	17,071	18,187	15,987	14,850	13,142	15,154	17,961	18,188	19,146	＋1,184	＋6.6
   Accounts Payables	M	2,278	3,087	4,081	2,872	3,287	3,429	4,254	4,358	3,782	4,455	＋96	＋2.2
   Retained Earnings	M	25,091	30,499	35,912	35,352	38,890	42,741	47,291	53,455	52,035	54,507	＋1,052	＋2.0
   Interest-Bearing Debt	M	9,396	9,987	11,538	10,396	8,352	6,883	4,634	3,973	3,864	3,812	(161)	(4.1)
   Net Debt	M	2,663	1,968	1,983	(3,311)	(7,705)	(11,473)	(8,034)	(7,041)	(3,602)	(5,818)	＋1,223	(17.4)
   Invested Capital*1	M	50,484	56,484	63,156	61,663	62,714	63,148	62,151	62,648	61,154	63,645	＋996	＋1.6
   Working Capital*2	M	23,632	26,161	27,868	26,260	24,000	22,937	24,183	27,433	28,577	29,125	＋1,692	＋6.2

   *1 A sum of interest-bearing debt and shareholder's equity

   *2 Accounts receivables + Inventory - Accounts payables

3. Consolidated Cash Flows

   Amounts less than the indicated unit are rounded down.

   	FY3/2018	FY3/2019	FY3/2020	FY3/2021	FY3/2022	FY3/2023	FY3/2024	FY3/2025	FY3/2026
   	FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A		H1 A
   Operating Cash Flows M	4,450	7,037	7,096	11,432	10,246	11,201	6,918	9,113		3,495
   Investing Cash Flows M	(9,161)	(9,964)	(4,419)	(3,731)	(1,131)	(2,461)	(4,056)	(1,801)		(1,023)
   Financing Cash Flows M	11,294	(1,783)	(1,136)	(3,720)	(6,804)	(6,476)	(8,553)	(9,040)		(3,880)
   Others M	1	(3)	(4)	172	38	35	4	74		24
   Net change in cash and cash equiva M	6,584	(4,713)	1,536	4,153	2,349	2,298	(5,688)	(1,654)		(1,384)
   Cash and cash equivalents at end of M	12,732	8,018	9,555	13,708	16,058	18,357	12,669	11,014		9,630

4. Financial Indicators

   Amounts less than the indicated unit are rounded down.
   		FY3/2018	FY3/2019	FY3/2020	FY3/2021	FY3/2022	FY3/2023	FY3/2024	FY3/2025	FY3/2026					FY3/2026
   		FY	FY	FY	FY	FY	FY	FY	FY	Q1	Q2		H1		H1	H2	FY
   		A	A	A	A	A	A	A	A	A	A		A		E	E	E
   No. of Issued Shares at YR-End (incl. treasury shares)	K	90,419	90,419	85,419	85,419	85,419	82,919	75,758	75,758	71,300	71,300		71,300		ー	ー	ー
   No. of Treasury Shares at YR-End*1	K	10,005	10,005	5,165	5,050	5,500	4,999	829	5,661	1,185	1,143		1,143		ー	ー	ー
   Ave No. of O/S Shares at YR-End (excl. treasury shares)*2	K	75,914	80,414	80,251	80,322	80,367	78,116	76,122	70,890	70,102	70,156		70,129		ー	ー	ー
   EPS*3		98.51	96.05	96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.24		68.08		64.17	69.13	133.30
   BPS		510.81	578.01	640.54	638.36	682.79	721.20	775.43	854.74	832.15	868.99		868.99		ー	ー	928.71
   DPS		28.75	29.00	29.00	49.00	38.00	38.00	42.00	53.00	ー	ー		ー		ー	ー	54.00
   DOE	%	7.3	5.3	4.8	7.7	5.8	5.4	5.6	6.5	ー	ー		ー		ー	ー	6.1
   Payout Ratio	%	29.2	30.2	30.0	196.7	40.8	43.1	42.5	40.3	ー	ー		ー		ー	ー	40.5
   ROE	%	24.2	17.6	15.8	3.9	14.1	12.4	13.2	15.8	ー	ー		ー		ー	ー	15.0
   ROA	%	21.2	16.8	14.6	14.2	13.7	14.8	14.3	16.6	ー	ー		ー		ー	ー	16.8
   ROIC*4	%	14.7	13.7	12.1	11.5	11.1	11.9	12.1	13.7	ー	ー		ー		ー	ー	13.8
   Capital-to-Asset Ratio	%	67.4	68.6	68.5	70.3	74.5	75.3	79.0	79.8	82.0	81.0		81.0		ー	ー	81.6
   Receivabes Turnover Period	Day	101	98	91	96	91	90	94	89	ー	ー		ー		ー	ー	86
   Inventory Turnover Period	Day	277	316	285	276	249	234	253	283	ー	ー		ー		ー	ー	280
   Payables Turnover Period	Day	48	55	58	56	50	56	69	70	ー	ー		ー		ー	ー	67
   Cash Conversion Cycle	Day	330	359	319	315	290	268	279	302	ー	ー		ー		ー	ー	300
   Number of Employees (Consolidated)	Person	906	932	1,074	1,167	1,205	1,166	1,216	1,250	ー	ー		ー		ー	ー	ー
   *1 Company shares held by the BIP Trust for directors and Company shares held by the Trust for the Trust-type Employee Shareholding Incentive Plan (E-Ship) are included in treasury shares. (E-Ship terminated on July 29, 2021)
   *2 Values for each Q are for the accounting period
   *3 EPS after taking into account the stock split. A 1:2 stock split was carried out in Jan. 2018. In light of this, EPS for FY3/2018 is calculated assuming that the stock split took place at the beginning of the fiscal year
   *4 Denominator profit is operating profit after tax. After-tax operating profit = operating profit *(1 - effective tax rate (30.62%))

5. Sales by Product

   FY3/2018 FY3/2019 FY3/2020 FY3/2021 FY3/2022 FY3/2023 FY3/2024 FY3/2025

   FY3/2026

   Amounts less than the indicated unit are rounded down.

   FY3/2026

   Pacemaker*6 M

   ICD*6 M

   Others M

   Cardiac Rhythm Management TTL M (CRM YoY) %

   EP Catheter M

   ABL Catheter M

   Others M

   EP/Ablation TTL M

   (EP/ABL YoY) %

   Artificial Heart Valve M

   Vascular Graft M

   Blood Purification*1 M

   Others*3*5 M

   Cardiovascular*４TTL M (CV YoY) %

   FY A

   6,463

   584

   200

   7,247

   ＋9.5

   15,354

   1,161

   3,848

   20,364

   ＋16.2

   1,742

   8,482

   1,131

   106

   11,464

   ＋26.0

   FY A

   5,169

   496

   196

   5,862

   (19.1)

   17,028

   1,369

   4,662

   23,060

   ＋13.2

   1,448

   9,133

   1,070

   77

   11,730

   ＋2.3

   FY A

   5,682

   5,960

   223

   11,866

   ＋102.4

   17,915

   1,421

   5,358

   24,696

   ＋7.1

   259

   8,879

   994

   32

   10,166

   (13.3)

   FY A

   5,996

   7,001

   250

   13,248

   ＋11.7

   17,314

   1,047

   5,501

   23,863

   (3.4)

   ー

   9,039

   ー

   929

   9,969

   (1.9)

   FY A

   5,899

   6,747

   330

   12,977

   (2.0)

   18,412

   1,232

   5,455

   25,099

   ＋5.2

   ー

   9,368

   ー

   748

   10,117

   ＋1.5

   FY A

   4,979

   7,049

   374

   12,403

   (4.4)

   19,654

   1,011

   5,626

   26,292

   ＋4.8

   ー

   10,353

   ー

   423

   10,776

   ＋6.5

   FY A

   5,241

   7,857

   402

   13,501

   ＋8.9

   21,211

   840

   2,197

   24,249

   (7.8)

   ー

   10,956

   ー

   449

   11,406

   ＋5.9

   FY A

   4,506

   8,296

   464

   13,267

   (1.7)

   22,543

   647

   4,654

   27,845

   ＋14.8

   ー

   11,688

   ー

   517

   12,206

   ＋7.0

   Q1 A

   1,049

   2,136

   199

   3,386

   (2.4)

   5,653

   87

   1,535

   7,276

   ＋2.5

   ー

   2,848

   ー

   161

   3,010

   ＋8.1

   Q2 A 960

   2,094

   225

   3,280

   ＋0.8

   5,708

   73

   1,647

   7,430

   ＋5.8

   ー

   2,685

   ー

   240

   2,926

   ＋1.9

   YoY (138)

   ＋58

   ＋104

   ＋24

   (2)

   (114)

   ＋525

   ＋408

   ー

   (34)

   ー

   ＋89

   ＋55

   % (12.6)

   ＋2.9

   ＋85.9

   ＋0.8

   (0.0)

   (60.8)

   ＋46.8

   ＋5.8

   ー

   (1.3)

   ー

   ＋59.3

   ＋1.9

   H1 A

   2,009

   4,230

   425

   6,666

   (0.9)

   11,362

   161

   3,182

   14,707

   ＋4.1

   ー

   5,534

   ー

   402

   5,936

   ＋5.0

   YoY (470)

   ＋216

   ＋194

   (59)

   (320)

   (230)

   ＋1,135

   ＋583

   ー

   ＋127

   ー

   ＋153

   ＋280

   % (19.0)

   ＋5.4

   ＋84.1

   (0.9)

   (2.7)

   (58.8)

   ＋55.4

   ＋4.1

   ー

   ＋2.4

   ー

   ＋61.6

   ＋5.0

   H1 E

   2,160

   4,320

   400

   6,880

   ＋2.3

   11,680

   215

   2,705

   14,600

   ＋3.4

   ー

   5,590

   ー

   280

   5,870

   ＋3.8

   H2 E

   1,980

   3,890

   480

   6,350

   (2.9)

   11,730

   195

   2,620

   14,545

   ＋6.0

   ー

   6,540

   ー

   240

   6,780

   ＋3.5

   FY E

   4,140

   8,210

   880

   13,230

   (0.3)

   23,410

   410

   5,325

   29,145

   ＋4.7

   ー

   12,130

   ー

   520

   12,650

   ＋3.6

   YoY (366)

   (86)

   ＋415

   (37)

   ＋866

   (237)

   ＋670

   ＋1,299

   ー

   ＋441

   ー

   ＋2

   ＋443

   % (8.1)

   (1.0)

   ＋89.6

   (0.3)

   ＋3.8

   (36.7)

   ＋14.4

   ＋4.7

   ー

   ＋3.8

   ー

   ＋0.5

   ＋3.6

   Neurovascular*5*7 M

   Neurovascular TTL M (NV YoY) %

   Gastrointestinal M

   Others*3 M

   Gastrointestinal*2*3TTL M (GI YoY) %

   Consolidated Net Sales M (Consolidated Net Sales YoY) %

   *1 Included in "Others" since FY3/2021

   ーーー

   28

   3,193

   3,221

   ＋15.7

   42,298

   ＋13.8

   ーーー

   107

   4,765

   4,872

   ＋51.2

   45,525

   ＋7.6

   ーーー

   132

   4,900

   5,032

   ＋3.3

   51,761

   ＋13.7

   ーーー

   247

   3,957

   4,204

   (16.5)

   51,286

   (0.9)

   12

   12

   ー

   453

   2,808

   3,261

   (22.4)

   51,469

   ＋0.4

   230

   230

   ＋1,753.6

   654

   1,394

   2,048

   (37.2)

   51,750

   ＋0.5

   912

   912

   ＋296.7

   925

   388

   1,314

   (35.8)

   51,384

   (0.7)

   1,842

   1,842

   ＋101.9

   1,345

   103

   1,448

   ＋10.2

   56,610

   ＋10.2

   562

   562

   ＋61.9

   352

   28

   380

   ＋23.9

   14,616

   ＋4.3

   624

   624

   ＋38.0

   394

   12

   406

   ＋9.0

   14,668

   ＋5.0

   ＋171 ＋38.0

   ＋171 ＋38.0

   ＋70 ＋21.6

   (36) (75.3)

   ＋33 ＋9.0

   ＋693 ＋5.0

   1,187

   1,187

   ＋48.4

   747

   40

   787

   ＋15.7

   29,285

   ＋4.6

   ＋387 ＋48.4

   ＋387 ＋48.4

   ＋149 ＋25.0

   (42) (51.4)

   ＋107 ＋15.7

   ＋1,299 ＋4.6

   1,045

   1,045

   ＋30.6

   840

   65

   905

   ＋33.0

   29,300

   ＋4.7

   1,215

   1,215

   ＋16.6

   1,055

   55

   1,110

   ＋44.4

   30,000

   ＋4.8

   2,260

   2,260

   ＋22.7

   1,895

   120

   2,015

   ＋39.1

   59,300

   ＋4.8

   ＋417 ＋22.7

   ＋417 ＋22.7

   ＋549 ＋40.9

   ＋16 ＋15.7

   ＋566 ＋39.1

   ＋2,689 ＋4.8

   *2 Renamed from "Transvascular Intervention" to "Gastrointestinal/PI" since FY3/2023

   *3 Renamed from "Gastrointestinal/PI" to "Gastrointestinal" since FY3/2024 as PI businesses are downsized. Its subcategory "PI-related" is renamed to "Others". Sales of structural heart disease-related is moved to "Cardiovascular, Others" (Reclassifications)

   *4 Renamed from "Cardiovascular Surgery" to "Cardiovascular" since FY3/2024

   *5 Sales of neurovascular-related is moved from "Cardiovascular, Others" to an new independent category of "Cardiovascular, Neurovascular" (Reclassifications)

   *6 Sales of left ventricular pacing lead is moved from "ICD" to "Pacemaker" since FY3/2024 (Reclassifications)

   *7 Sales of neurovascular in the sub-groupe of CV is moved to a new independent main groupe (Reclassifications)

   *8 Reclassifications regarding *3, *5, *6, and *7 are retroactively applied to FY2021 and onward.

6. Products Included in Product Categories (As of Sep. 2025)

*Listed in descending order of composition ratio. *Red text indicates items defined as "Core Products." *Underlined text indicates proprietary products.